Ranbaxy Q3 top-line seen up 33% at Rs 2698 crore

NEW DELHI: Ranbaxy Laboratories Ltd is slated to come out with its third quarter results for the financial year 2012 on Thursday.

The company is expected to report a 33 per cent jump in its net sales for the quarter ended September 30 to Rs 2698 crore from Rs 2028 crore reported in the year-ago period, according to ET NOW estimates.

Adjusted PAT is seen at Rs 254 crore, up 109 per cent from Rs 121 crore reported in the year-ago period. The drug major reported a net loss after tax and minority interest of Rs 464.58 crore for the quarter ended September 30, 2011, on account of foreign exchange losses.

The company follows January-December financial year.

EBITDA is seen at Rs 390 crore, or 124 per cent jump, in the second quarter of the financial year 2012, compared to Rs 174 crore in the year ago period. EBITDA margins are likely to expand to 14.4 per cent from 8.5 per cent reported in the year ago period.